Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial

摘要: PURPOSEStudies conducted by the Eastern Cooperative Oncology Group (ECOG) indicate both paclitaxel and carboplatin are associated with an improvement in 1-year survival patients stage IV non-small-cell lung cancer (NSCLC). Based on these findings, a phase II trial of agents combination was advanced NSCLC.PATIENTS AND METHODSEligibility included previously untreated IIIB or NSCLC good performance status (PS). Paclitaxel (135 175 mg/m2) administered 24-hour infusion day 1, followed 1-hour 2 (300 mg/m2 dosed to area under concentration-time curve [AUC] 6 mg/mL.min). Treatment repeated every 28 days for total six cycles. Hematopoietic growth factors were not routinely used.RESULTSAmong 51 eligible patients, there no complete 14 partial responses, overall response rate 27% (95% confidence interval [CI], 17% 41%). The median progression-free t...